Document Type: Research Articles
Department of Medical Oncology, Memorial Hospital, Istanbul, Turkey.
Department of Thoracic Surgery, Yedikule Education and Research Hospital, Istanbul, Turkey.
Department of Medical Oncology, Istanbul University, Istanbul, Turkey.
Objective: Despite the existence of detailed consensus guidelines, challenges remain regarding the role angiogenetic
factors on non-small cell lung cancer (NSCLC). This study was conducted to determine the role of the vascular endothelial
growth factor (VEGF), interleukin-8 (IL-8) and angiopoietin2 (Ang2) in patients with NSCLC. Methods: This study
included 64 consecutive patients with non-small cell lung cancer, who admitted to clinic. Pre-treatment serum VEGF, IL-8
and Ang2 levels were evaluated. Patients were treated according to internationally accepted guidelines. Results: VEGF
and IL-8 serum levels of patients with both squamous cell carcinoma and adenocarcinoma were significantly higher
than controls (p<0.05). In addition, IL-8 levels were lower among treatment-responders than non-responders (p:0.031).
Impact of elevated or decreased levels of VEGF, Ang2 and IL-8 on survival was evaluated, accepting median level as
reference. There was no correlation between the serum levels of VEGF, Ang2, IL-8 and survival. Conclusion: We found
that the levels of angiogenic markers were significantly different between non-small cell lung cancer patients and
controls. These markers could elicit more information related to stage and prognosis.